Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 1 opinions in the last 12 months.
Natera, trading under the symbol NTRA-Q, has shown remarkable performance with a 145% increase in its stock price over the past year. The company is noted for its strong presence in the cancer detection and recurrence market, indicating a solid franchise that is likely to continue providing value. Experts express a positive outlook for Natera, highlighting not only its impressive growth but also its long-term potential in an essential health sector. Given its innovative solutions and the increasing demand for cancer detection technologies, Natera is well-positioned for ongoing success. Overall, experts appear to favor Natera for both short-term gains and long-term investment opportunities.
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
In the last year, 1 stock analyst published opinions about NTRA-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
On 2025-05-02, Natera (NTRA-Q) stock closed at a price of $156.66.
Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.